Register
Login:
Share:
Email Facebook Twitter




Add Immupharma to quick picks

Immupharma Share Price (IMM)



Share Price Information for Immupharma (IMM)


Share Price: 45.00Bid: 44.00Ask: 46.00Change: 0.00 (0.00%)No Movement on Immupharma
Spread: 2.00Spread as %: 4.55%Open: 45.00High: 45.00Low: 45.00Yesterday’s Close: 45.00
InfoCFDs vs Share Trading - Download your Free Guide from London South East Markets
When trading CFDs, Forex, and Spread bets, it is possible to lose more than your initial deposit.


Immupharma Plc Ord 10P

Immupharma is listed in the FTSE AIM All-Share
Immupharma is part of the Pharmaceuticals & Biotechnology sector






Share Price SpacerPrice
45.00

Share Price SpacerBid
44.00

Share Price SpacerAsk
46.00

Share Price SpacerChange
0%0.00

Share Price SpacerVolume
14,361

Share Price SpacerOpen
45.00

Share Price SpacerHigh
45.00

Share Price SpacerLow
45.00

Share Price SpacerClose
45.00

Share Price SpacerCurrency
GBX


Currency Issue Country Shares in Issue Market Capitalisation Market Size
GBX GB 88.62m £39.88m 5,000

52 Week High 66.00 52 Week High Date 3-NOV-2014
52 Week Low 42.50 52 Week Low Date 22-SEP-2014

# Trades Vol. Sold Vol. Bought PE Ratio Earnings Dividend Yield
5 8,188 6,173 -13.120 -3.43 0.00 0.00




Date
Time
Trade Prc
Volume
Buy/Sell
Bid
Ask
Value
 

03-Jul-15
15:21:37
45.30
1,000
Buy* 
44.00
46.00
453.00
Trade Type:
Ordinary

03-Jul-15
09:49:40
44.33
8,000
Sell* 
44.00
46.00
3,546
Trade Type:
Ordinary

03-Jul-15
08:54:00
45.45
2,173
Buy* 
44.00
46.00
987.63
Trade Type:
Ordinary


*Buys and Sells are calculated on the difference between the trade price and the current mid price. As such, they can occasionally be incorrect.

View more Immupharma trades >>

Directors Deals for Immupharma (IMM)
Trade DateActionNotifierPriceCurrencyAmountHolding
30-Apr-15Notification of Holding
Trade Notifier Information for Immupharma
Stephane Robert George Mery held the position of Non-Executive Director at Immupharma at the time of this trade.
 Stephane Robert George Mery
002259
24-Jan-13Sell
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
57GBX62,1690
24-Jan-12Buy
Trade Notifier Information for Immupharma
Ajay Agrawal held the position of Non-Executive Director at Immupharma at the time of this trade.
 Ajay Agrawal
80GBX62,1690
View more Immupharma directors dealings >>

Date/Time
Author
Subject
Share Price
Opinion
Fri 11:11
TurnaShilling
RE: Leas
45.00
No Opinion

Is this the first time one of your posts has been removed , It has happened to the best &very best of posters on this B .B. Welcome to the ( post removed )club . The majority of folk enjoy your feminine input & would be sadly miss if you abandon us , All will soon be forgiven !!!
Thu 22:04
khameeleon
RE: Leas
45.00
No Opinion

Good posts chaps....the standard of admin is patchy at best, some absolutely scandalous posting across the boards. Frustrating share, but good comment b o b re the OSE /Simbec timescales.....
Thu 17:23
boomorbust
Leas
45.00
No Opinion

I guess for your post to be removed someone must have reported it and therefore can only assume you hit a nerve there. Must be difficult for Admin. but just lately have seen the most disgraceful posts on other bbs go unchecked. A quick look at posting history usually tells you all you need to know.
Thu 17:16
leas
RE: 5 years on
45.00
No Opinion

appears my comments in relation to double identities and the same member ramping STG and NEW have been removed. One company now sitting at almost at a MC of 50% lower and the other suspended. Yet a 'new' member to LSE can suggest that this BoD's may be acting fraudulently. If I wore a red badge then I would be asking for a refund. Mind boggling hypocrisy. LSE is a site to feed the ego's of 10 bob millionaires and investors better placed at a roulette table. LSE feel free to remove my democratic right to freedom of speech. Better still, delete my account, no advantage to be gained being a member.
Thu 17:03
boomorbust
win
45.00
No Opinion

They are a French biotech. company. At roughly the same time IMM announced that Simbec-Orion had been appointed as CRO for the Lupuzor trial OSE Pharms also appointed Simbec to run their phase III oncology trial. The RNS for that OSE Pharma included a paragraph re. timelines and what happens next and perhaps did a much better job of managing shareholders expectations. I'm not sure whether the same timelines would apply to Immupharma but it would certainly make sense and explain this news void. This is what they had to say:- "Simbec-Orion has started the feasibility study for the planned study with international clinical experts and patient enrolment is planned for the second half of 2015. Simbec-Orion will be responsible for site selection, patient enrolment, clinical monitoring, data management, statistical analysis and regulatory affairs." http://www.investegate.co.uk/simbec-orion-grp-ld/rns/ose-pharma-collaboration-for-cancer-trial/201501291101174914D/
Thu 16:20
winorlose1987
Boom
45.00
No Opinion

who are OSE PHARMA,

Share prices shown are taken at time of message posting.
Thread ViewThread View
View more share chat for Immupharma (IMM) >>
Please Login or Register to post messages






Sign up for Live Prices


CD02WL.001.081313


Home  |  Contact Us  |  About Us  |  Careers  |  Advertise with Us  |  Sitemap  |  Terms & Conditions  |  Cookies  |  Privacy


Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.